Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2006

View Archived Issues

DTA-H19: a new DNA-based cancer therapy

7TM Pharma receives milestone payment from research collaboration with P&G

BGC-20-761 improves in vivo cognitive benefits mediated via 5-HT6 antagonism

Spine Wave cleared to begin pilot trial of NuCore Injectable Nucleus

Rexahn partners with University of Maryland in nanomedicine

Nastech Pharmaceutical acquires RNAi program targeting influenza from Galenea

Targeting of IGF-IR and Bcl-2 eradicates androgen-independent prostate cells in vitro

mGluR III agonists: New restorers of neural circuits in Parkinson's disease?

Xanthus Life Sciences changes name to Xanthus Pharmaceuticals

Celtic Pharma licenses IDEA's Transfersome technology and derma pipeline

AP-5346 studied in head and neck cancer

Phase I study assesses safety of gene therapy product AGTC-0106

ZIO-201 begins phase I/II study in sarcoma

Alcon withdraws application to extend European approval of Opatanol

OrthoLogic to acquire certain assets of AzERx

Cyproxan receives Japanese approval for new indication

PEP-005 Topical gel well tolerated in dose-escalation study

In vivo metabolism of new combi-molecule facilitates potent multiple tumor targeting

Indole-3-carbinol and genistein target BRCA1 and BRCA2 genes

LA-12 overcomes cisplatin resistance in ovarian tumors in mice

Novel antiinfective agents disclosed in recent patent literature

Recent patents disclose novel ophthalmic drugs

New melanocortin MC4 receptor ligands prepared and tested by SCRAS

Phase II trial assesses cortisol synthesis inhibitor DIO-902 for type 2 diabetes

European approval for Rotarix

Oracea filed for approval in U.K.

EluSys presents new efficacy data for Anthim anthrax therapeutic

Ampligen plus oseltamivir or zanamivir synergistically inhibits avian influenza

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.